Together, these results emphasize the centrality of immune cell infiltration and pro-inflammatory signaling—particularly via TLR4/NF-κB activation driven by S100A8/A9 and SPP1—as promising mechanistic targets for therapeutic intervention in AF. Here, NFKB1 is linked to atrial fibrillation.